This website is for the U.S, for the other countries please refer to this link.
LONGITUDINAL FOLLOW-UP: SUDOSCAN DEMONSTRATED EFFICACY IN RESULTS FOLLOW-UP SUDOSCAN has proven its clinical utility in the follow-up of sudomotor function. In a Finnish study, SUDOSCAN
SUDOSCAN in Oncology : Chemotherapy InduCed Polyneuropathy Two studies evaluating SUDOSCAN Severe drug-induced neurotoxic adverse effects constitute the second most common cause of dose limitation
EASD 2019 POSTER: DIABETIC FOOT RISK DETECTION A multi-center study (3 hospitals: Bichat, La Pitié Salpêtrière, Bégin) completed in France established the link between the
Identification and Follow-Up of the at Risk Diabetic Foot Impeto Medical will present SUDOSCAN and the role of quantitative sudomotor testing during the 17th annual
Los Angeles, CA – February 14, 2017 — Impeto Medical CEO and Founder Philippe Brunswick is featured on the award-winning, global TV show, Worldwide Business
Promotional Communication. The medical devices SUDOSCAN is cleared by the US Food and Drug Administration (FDA). The test allows screening and monitoring of peripheral autonomic neuropathies. It can be performed in diabetic patients or in patients suffering from neurological diseases involving small fibers damage. As with any diagnostic test, its results must be interpreted in a global context including the clinic and other examinations performed. Please read the user manual instructions carefully. Contact our office for more information. Last update: 2021/01/12
